Pharmacokinetics of Tildrakizumab (MK ‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects
Basic&Clinical Pharmacology&Toxicology, EarlyView.
Source: Basic and Clinical Pharmacology and Toxicology - Category: Drugs & Pharmacology Authors: Sauzanne Khalilieh
,
Peter Hodsman
,
Christine Xu
,
Anjela Tzontcheva
,
Shirley Glasgow
,
Diana Montgomery Source Type: research
More News: Drugs & Pharmacology | Toxicology